Vimta Labs won't define capacity utilisation after giving 80-85% in January
Management refused to give a percentage for new facilities this call, despite having cited 80-85% utilisation for the EMI/EMC chamber just six months ago.
What's new
- Biologics facility commercialised with first order; client onboarded in Q1.
- Q1 total income ₹1,129 million, up 13.7% YoY; EBITDA ₹411 million, margin 36.4%.
- Food testing declined due to import/export disruption; domestic pivot partially offset.
- FY27 capex budget ~₹80 crore, with ~₹10 crore for biologics.
Themes from the call
Demand
Pharma CRO testing grew strongly YoY; food testing weakened on trade disruption; electronics stable with defence opportunities; biologics secured first order.
Margins
EBITDA margin 36.4%, down QoQ due to facility expenses, new labour-law costs and rupee appreciation, but up YoY.
Capital allocation
FY27 capex ~₹80 cr, phased against visibility; ~₹10 cr for biologics; routine capex linked to prior-year depreciation.
Guidance watch
- Biologics expected to contribute meaningfully from third year onward, not this year; no contribution percentage given.
- Existing facilities support growth for 4-5 years; annual capex typically equals prior-year depreciation.
- Margins not to decline further, but no quantitative floor or target provided.
- Refused to give numerical FY27 revenue projection, biologics order size, customer identity, or additional-client timing.
Risk flags
- Capacity utilisation disclosure inconsistency raises questions about transparency on capex returns.
- Food testing half-exposed to import/export disruption; domestic pivot may not fully compensate.
- Management refused to quantify many guidance items, leaving limited visibility on growth trajectory.
Key quotes
-
"The commercialization has begun already in Q1. The client is onboarded in Q1."
— Harita Vasireddy, Managing Director, on biologics -
"Therefore, uh, we wouldn't really um, define capacities as percentages at any point of time. Uh, especially when it comes to uh, new capacities that we have created in terms of buildings."
— Vimta Labs management, July 2026 call
The brief
Vimta Labs entered a new chapter this quarter: its biologics facility secured its first commercial order, and the client is onboarded. The Q1 numbers look solid — revenue of ₹1,129 million, EBITDA margin at 36.4%, net debt-free with cash of ₹628.2 million. But the same call contained a disclosure reversal that undermines the story. In January, management said the current EMI/EMC chamber was running at 80-85% utilisation. This quarter, when asked about the new facilities, management said it would not define capacities as percentages at any point. The reason — something about new buildings — was vague. Investors who used the January number to model capex returns now have no benchmark. The biologics order is a genuine milestone. It extends Vimta's life-sciences platform and opens a cross-sell opportunity with its existing pharma clients, where retention runs above 90%. But management also refused to quantify the order size, the customer, or when a second client might come. Meaningful revenue and margin contribution, they said, starts only in the third year. Elsewhere, food testing remains a drag. Half the business is exposed to import-export flows, which weakened on global trade friction. A domestic pivot helped some, but management acknowledged the business could have done better without the disruption. Capex discipline is intact: ₹80 cr for FY27, with only ₹10 cr for biologics and the rest routine. But the capacity-utilisation flip-flop makes it harder to assess whether the ₹100 cr spent on Genome Valley facilities is earning its keep. Vimta's first biologics order is real progress, but a shifting disclosure stance doesn't inspire confidence.
Vimta's biologics milestone is real, but a shifting disclosure stance doesn't inspire confidence in the capex story.